| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01605318 Details | 2024-01-24 Interventional | 1/2 | 92 | Immunoconjugate… Irinotecan Labetuzumab Colonic Neoplas… Colorectal Neop… Rectal Neoplasm… Colon Cancer Metastatic Colo… Rectal Cancer | - - | |||
| NCT01083966 Details | 2024-01-24 Interventional | 1 | - | Bevacizumab Neurilemmoma Neuroma, Acoust… Vestibular Schw… | - - | |||
| NCT05848843 Details | 2024-01-23 Interventional | 1 | 0 | Adagrasib Durvalumab Gastrointestina… Intestinal Neop… Lung Neoplasms Gastro-intestin… Lung Cancer | 0 participant accrual - | |||
| NCT05238831 Details | 2024-01-23 Interventional | 1 | 0 | Ado-Trastuzumab… Albumin-Bound P… Alectinib Anastrozole Antibodies Antibodies, Mon… Antineoplastic … Atezolizumab Bevacizumab Capecitabine Carboplatin Endothelial Gro… Entrectinib Fulvestrant Immunoconjugate… Immunoglobulin … Immunoglobulins Irinotecan Letrozole Maytansine Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Phosphoinositid… Trastuzumab Trastuzumab bio… Vemurafenib Vinorelbine Breast Neoplasm… Carcinoma Carcinoma, Ovar… Ovarian Neoplas… Pancreatic Neop… Prostatic Neopl… Recurrence Sarcoma Advanced Breast… Advanced Malign… Advanced Ovaria… Advanced Pancre… Advanced Prosta… Advanced Sarcom… Anatomic Stage … Anatomic Stage … Recurrent Adult… Recurrent Breas… Recurrent Ovari… Recurrent Prost… Stage II Pancre… Stage III Ovari… Stage III Pancr… Stage IV Ovaria… Stage IV Pancre… | Withdrawn due to a change in therapeutic interventions. - | |||
| NCT05208840 Details | 2024-01-23 Interventional | 4 | 0 | Ocrelizumab Inflammation Multiple Sclero… Sclerosis | Due to deterioration of the geopolitical situation and escalation of conflict between Russia
and Ukraine ML42302 study was put on hold. - | |||
| NCT05189977 Details | 2024-01-23 Interventional | 1 | 34 | Prazosin Propranolol Stress Disorder… Stress Disorder… Post-traumatic … | The decision to terminate the trial early was not based on safety concerns. The trial was
terminated early due to some implausible blood pressure values being captured, which was the
primary endpoint of the study. - | |||
| NCT05183828 Details | 2024-01-23 Interventional | 4 | - | Letrozole Breast Neoplasm… Carcinoma Carcinoma, Duct… Anatomic Stage … Anatomic Stage … Anatomic Stage … Breast Adenocar… Invasive Breast… | Enrollment temporarily on hold for data analysis - | |||
| NCT04996030 Details | 2024-01-23 Interventional | 1 | 16 | Arsenic Trioxid… Leukemia Leukemia, Promy… Acute Promyeloc… | Prioritization - | |||
| NCT04711161 Details | 2024-01-23 Interventional | 1 | - | Paclitaxel Fallopian Tube … Ovarian Neoplas… Ovarian Tumors | Business/Commercial Reasons - | |||
| NCT05162131 Details | 2024-01-22 Interventional | 1 | 34 | Ticagrelor Healthy | After recruitment of Cohorts 1-4 was completed, Sponsor decided to terminate study, initially
due to COVID and then considering that PK data from the dose planned to be tested in Cohort 5
(18000 mg) would be available from the ongoing Phase 3 study. - | |||
| NCT04458909 Details | 2024-01-22 Interventional | 3 | 15 | Carboplatin Cisplatin Gemcitabine Nivolumab Carcinoma Carcinoma, Squa… Nasopharyngeal … Recurrence Metastatic Naso… Metastatic Naso… Metastatic Naso… Metastatic Naso… Nasopharyngeal … Recurrent Nasop… Recurrent Nasop… Recurrent Nasop… Stage IV Nasoph… Stage IVA Nasop… Stage IVB Nasop… | External information - | |||
| NCT04000529 Details | 2024-01-22 Interventional | 1 | 122 | Spartalizumab Carcinoma Carcinoma, Non-… Esophageal Squa… Gastrointestina… Squamous Cell C… Colorectal Canc… Esophageal SCC Head and Neck S… Non-small Cell … | Business reasons - | |||
| NCT03500874 Details | 2024-01-22 Interventional | 3 | 92 | Floxuridine Fluorouracil Irinotecan Leucovorin Oxaliplatin Colorectal Neop… Neoplasm Metast… Colorectal Canc… HAI Liver Metastase… | The study was terminated prematurely due to FUDR production halt in China - | |||
| NCT05482074 Details | 2024-01-19 Interventional | 2 | 0 | Olaparib Melanoma Melanoma, Cutan… Cutaneous Melan… Mucosal Melanom… Recurrent Metas… Uveal Melanoma | Principal Investigator left the institute - | |||
| NCT04254107 Details | 2024-01-19 Interventional | 1 | 132 | Brentuximab Ved… Carcinoma Lymphoma Lymphoma, Large… Lymphoma, T-Cel… Squamous Cell C… Stomach Neoplas… Triple Negative… Bladder Cancer Cervical Cancer Classical Hodgk… Cutaneous Melan… Diffuse Large B… Gastric Carcino… Gastroesophagea… Head and Neck S… Non-small Cell … Ovarian Cancer Peripheral T-ce… Triple Negative… | Study closed due to portfolio prioritization - | |||
| NCT03742349 2018-002244-82 Details | 2024-01-19 Interventional | 1 | 64 | Spartalizumab Breast Neoplasm… Triple Negative… Triple Negative… | This was a sponsor decision and was not a consequence of any safety concern - | |||
| NCT06210945 Details | 2024-01-18 Interventional | 2 | - | Streptococcal p… Scleroderma, Di… Scleroderma, Sy… Sclerosis Systemic Sclero… | pending financial resources - | |||
| NCT05479045 Details | 2024-01-18 Interventional | 2 | - | Nivolumab Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer … Ovarian Cancer … Ovarian Cancer … | Protocol Amendment pending - | |||
| NCT05126966 2021-003226-71 Details | 2024-01-18 Interventional | 3 | 0 | Aflibercept Ranibizumab Macular Degener… Wet Macular Deg… Neovascular Age… | Roche/Genentech has initiated an immediate pause of all new PDS implantations because the
implants from commercial supply in the clinical studies did not meet the filed specifications
for the intended use - | |||
| NCT04866017 2020-004656-14 Details | 2024-01-18 Interventional | 3 | 63 | Durvalumab Tislelizumab Carcinoma, Non-… Lung Neoplasms Non Small Cell … | This decision was conducted by the sponsor and not driven by safety concerns as no new safety
signals have been observed in the ociperlimab program. - |